Comparison of the effects and clinical application analysis of telisotuzumab-EMRELIS and CAR-T therapy

Telisotuzumab (trade name EMRELIS) is a monoclonal antibody drug conjugate ( ADC), mainly used to treat patients with non-small cell lung cancer (NSCLC) with high expression of c-Met. Its mechanism is to accurately recognize c-Met receptors on the surface of tumor cells through antibodies and deliver cytotoxic drugs directly into tumor cells, thereby enhancing the specificity of anti-tumor effects and reducing toxicity to normal tissues. Clinical studies have shown that terituzumab exhibits considerable response and disease control rates in advanced NSCLC, especially in patients who have failed standard treatments, providing a new treatment option for patients who cannot tolerate traditional chemotherapy or who have failed targeted therapies.

In contrast, CAR-Tcell therapy is a type of immunotherapy that uses genetic engineering to modify the patient's own T cells so that they can specifically recognize tumor antigens and achieve cell killing. CAR-Ttherapy has achieved remarkable results in hematological tumors such as acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL), which is characterized by efficient and sustained immune attack capabilities. However, the application of CAR-T in solid tumors is limited by factors such as immunosuppression in the tumor microenvironment, insufficient T cell infiltration, and tumor heterogeneity, resulting in less than ideal efficacy for hematological tumors. In addition, serious side effects of CAR-T therapy such as cytokine release syndrome (CRS) and neurotoxicity also increase the risks of clinical use and the difficulty of management.

The comparison between terituzumab and CAR-T therapy can be analyzed from three aspects: efficacy, safety and accessibility. First of all, in terms of efficacy, terituzumab has shown controllable response rates and disease stabilization rates against c-Met positive tumors, and is suitable for patients with advanced NSCLC, while CAR-TOverall response rates are relatively limited in solid tumors. Secondly, from a safety perspective, the adverse reactions of terituzumab mainly include hematological toxicity, fatigue, mild to moderate nausea and fluctuations in liver function indicators. Side effects can be controlled through dose adjustment and supportive treatment. However, CAR-T therapy has potentially fatal risks, such as CRS and neurotoxicity, which requires close monitoring in professional centers. Finally, in terms of accessibility, terituzumab, as an ADC drug, adopts intravenous administration and can be operated in conventional tumor treatment centers without complex cell modification processes. However, CAR-T therapy requires high cell processing and personalized preparation, is expensive, and has a long treatment cycle, which limits its wide application.

In clinical application, terituzumab is suitable for NSCLC patients with high c-Met expression and failure of conventional treatments, especially advanced patients who have progressed after receiving chemotherapy and other targeted therapies. According to existing research data, the drug has the potential to further improve the efficacy and prolong progression-free survival when combined with other immune checkpoint inhibitors or chemotherapy regimens. In contrast, CAR-T therapy is still mainly used in hematological tumors, and the treatment of solid tumors is still in the exploratory stage. Taken together, terituzumab, with its specific targeting, good tolerability and ease of operation, provides a feasible and safe treatment option for patients with advanced NSCLC, while CAR-T therapy has shown breakthrough efficacy in specific hematological tumors, but more clinical verification and technical optimization are still needed in solid tumors.

Keyword tags: terituzumab, CAR-Tcomparison, c-Met, non-small cell lung cancer, ADC drugs, solid tumors, immunotherapy, efficacy, safety.

Reference:https://en.wikipedia.org/wiki/Telisotuzumab_vedotin